fluoxetine and Aging
fluoxetine has been researched along with Aging in 73 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study is to verify whether LAC can have an antidepressant action in a population of elderly patients with dysthymic disorder in comparison with a traditional antidepressant such as fluoxetine." | 9.17 | L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( Bersani, FS; Bersani, G; Colletti, C; Denaro, A; Koverech, A; Liberati, D; Meco, G; Nicolai, R, 2013) |
| "The authors compared the efficacy and side effects of fluoxetine and placebo in elderly outpatients with dysthymic disorder." | 9.11 | Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( Cheng, J; Devanand, DP; Nobler, MS; Pelton, GH; Roose, SP; Sackeim, HA; Turret, N, 2005) |
| " Aging decreases expression of mRNA for vasoactive intestinal peptide (VIP), a key neuropeptide for rhythm generation and photic phase shifts, and increases expression of serotonin transporters and 5-HT(1B) receptors, whose activation inhibits these phase shifts." | 7.76 | The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors. ( Duncan, MJ; Franklin, KM; Hester, JM; Hopper, JA, 2010) |
| "Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery." | 7.73 | Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006) |
| "Male F344BNF1 hybrid rats (F1 crosses between female Fischer 344 and male Brown Norway rats) aged 3 or 24 months were treated with vehicle (1 ml water/kg, IP) or fluoxetine (10 mg/kg, IP) once a day for 1 day or 27 consecutive days; body weights were recorded daily." | 7.68 | Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats. ( Alper, RH, 1992) |
| " In animal experiments, chronic administration of fluoxetine induces increased excitability of mature granule cells (GCs), enhancing axonal and dendritic reorganization, as well as promoting neurogenesis or angiogenesis in the dentate gurus (DG), but the effect of fluoxetine in the subventricular zone (SVZ) remains controversial." | 6.55 | Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. ( Qu, H; Sun, X; Sun, Y; Xiao, T; Zhao, C; Zhao, S, 2017) |
| "Fluoxetine treatment of old mice further increased hippocampal S100B, suggesting that aging does not interfere with fluoxetine's action on hippocampal S100B." | 5.32 | Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. ( Akhisaroglu, E; Akhisaroglu, M; Manev, H; Manev, R; Uz, T, 2003) |
| "The pharmacological and physiological effects of chronic administration of the selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor (SSRI) fluoxetine and the dual 5-HT/norepinephrine (NE) reuptake inhibitor duloxetine were compared on 5-HT-mediated electrophysiological responses recorded in the hippocampus of young (3-5 months) and old (17-20 months) female Fischer 344 rats." | 5.30 | Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus. ( Lakoski, JM; Smith, JE, 1998) |
| " The aim of the study is to verify whether LAC can have an antidepressant action in a population of elderly patients with dysthymic disorder in comparison with a traditional antidepressant such as fluoxetine." | 5.17 | L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( Bersani, FS; Bersani, G; Colletti, C; Denaro, A; Koverech, A; Liberati, D; Meco, G; Nicolai, R, 2013) |
| "The authors compared the efficacy and side effects of fluoxetine and placebo in elderly outpatients with dysthymic disorder." | 5.11 | Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( Cheng, J; Devanand, DP; Nobler, MS; Pelton, GH; Roose, SP; Sackeim, HA; Turret, N, 2005) |
| "After 1 month treatment, vortioxetine improved visuospatial memory and reduced depression-like behavior." | 3.85 | Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice. ( Gulinello, M; Li, Y; Sanchez, C, 2017) |
| " Here, we investigated the role of aging in the behavioral effects of the antidepressants, desipramine (DMI) (5, 10, and 20 mg/kg) and fluoxetine (FLX) (5, 10, and 20 mg/kg) in young adults (3-5 months), middle-aged (MA, 12-15 months), and senescent (SE, 23-25 months) male rats in the forced-swim test." | 3.83 | Age-related changes in the antidepressant-like effect of desipramine and fluoxetine in the rat forced-swim test. ( Fernández-Guasti, A; Martínez-Mota, L; Olivares-Nazario, M, 2016) |
| " Aging decreases expression of mRNA for vasoactive intestinal peptide (VIP), a key neuropeptide for rhythm generation and photic phase shifts, and increases expression of serotonin transporters and 5-HT(1B) receptors, whose activation inhibits these phase shifts." | 3.76 | The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors. ( Duncan, MJ; Franklin, KM; Hester, JM; Hopper, JA, 2010) |
| "Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery." | 3.73 | Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006) |
| "Male F344BNF1 hybrid rats (F1 crosses between female Fischer 344 and male Brown Norway rats) aged 3 or 24 months were treated with vehicle (1 ml water/kg, IP) or fluoxetine (10 mg/kg, IP) once a day for 1 day or 27 consecutive days; body weights were recorded daily." | 3.68 | Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats. ( Alper, RH, 1992) |
| " In animal experiments, chronic administration of fluoxetine induces increased excitability of mature granule cells (GCs), enhancing axonal and dendritic reorganization, as well as promoting neurogenesis or angiogenesis in the dentate gurus (DG), but the effect of fluoxetine in the subventricular zone (SVZ) remains controversial." | 2.55 | Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. ( Qu, H; Sun, X; Sun, Y; Xiao, T; Zhao, C; Zhao, S, 2017) |
| "Fluoxetine has a nonlinear pharmacokinetic profile." | 2.39 | Clinical pharmacokinetics of fluoxetine. ( Altamura, AC; Moro, AR; Percudani, M, 1994) |
| "The body weight was determined, and behavior tests, including sucrose preference test, forced swimming test and open field test were performed." | 1.56 | Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model. ( Wang, G; Wang, H; Xiao, L, 2020) |
| "Fluoxetine is an antidepressant, which exerts a powerful neurogenic effect on dentate gyrus progenitor cells, but is ineffective on stem cells." | 1.48 | Fluoxetine or Sox2 reactivate proliferation-defective stem and progenitor cells of the adult and aged dentate gyrus. ( Caruso, C; Ceccarelli, M; Coccurello, R; Costanzi, M; D'Andrea, G; Giacovazzo, G; Micheli, L; Tirone, F, 2018) |
| "Fluoxetine (FLX) is a selective serotonin (5-HT) reuptake inhibitor known for its effects modifying aggressiveness, personality traits, and anxiety-like behaviors." | 1.46 | Acute fluoxetine treatment increases aggressiveness in juvenile matrinxã (Brycon amazonicus). ( Barbosa Júnior, A; Serra, M; Urbinati, EC; Wolkers, CPB, 2017) |
| "Fluoxetine treatment in adulthood evokes antidepressant and anxiolytic responses." | 1.40 | Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior. ( Chachra, P; Desouza, LA; Kennedy, P; Nestler, EJ; Pena, CJ; Sarkar, A; Vaidya, VA, 2014) |
| "Depression is recognized as a predictor of increased cardiac morbidity and mortality." | 1.37 | Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging. ( Belzung, C; Camus, V; d'Audiffret, A; Isingrini, E, 2011) |
| "Fluoxetine has been reported to decrease the number of "mature" calbindin-positive cells in the dentate gyrus; we found this still occurred on the side of a CA3 lesion." | 1.37 | Novel control by the CA3 region of the hippocampus on neurogenesis in the dentate gyrus of the adult rat. ( Herbert, J; Liu, JX; Pinnock, SB, 2011) |
| " Dam dosing was adjusted to reflect the 50th and 85th percentiles of serum concentrations observed in pregnant women." | 1.37 | Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk. ( Bourke, CH; Capello, CF; Nemeroff, A; Newport, DJ; Owens, MJ; Ritchie, JC; Stowe, ZN, 2011) |
| "The fluoxetine treatment induced active somatic membrane properties resembling immature granule cells and markedly reduced synaptic facilitation that characterizes the mature dentate-to-CA3 signal transmission." | 1.36 | Reversal of hippocampal neuronal maturation by serotonergic antidepressants. ( Haneda, E; Ikeda, Y; Kobayashi, K; Miyakawa, T; Sakai, A; Suzuki, H; Yamasaki, N, 2010) |
| "Fluoxetine also did not increase forced swim struggle behavior in juvenile mice of all strains, but was effective in increasing struggle in adults." | 1.35 | Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. ( Baker, KB; Davis, KW; Gerhardt, B; Lanthorn, TH; Malbari, MM; Mason, SS; Pogorelov, VM; Ritter, R; Savelieva, KV; Wray, SP, 2009) |
| "Fluoxetine treatment increased GR mRNA in the hippocampus of young rats (24 and 46% increase in DG and CA3, respectively, P<0." | 1.31 | The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. ( Hibberd, C; Noble, J; Seckl, JR; Yau, JL, 2002) |
| "The pharmacological and physiological effects of chronic administration of the selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor (SSRI) fluoxetine and the dual 5-HT/norepinephrine (NE) reuptake inhibitor duloxetine were compared on 5-HT-mediated electrophysiological responses recorded in the hippocampus of young (3-5 months) and old (17-20 months) female Fischer 344 rats." | 1.30 | Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus. ( Lakoski, JM; Smith, JE, 1998) |
| "Fluoxetine-treated animals on the other hand, showed a great amplification of plasticity with a conspicuous sprouting of the uncrossed retinal axons into denervated areas." | 1.30 | Fluoxetine-induced plasticity in the rodent visual system. ( Amaral, AR; Bastos, EF; Marcelino, JL; Serfaty, CA, 1999) |
| "Fluoxetine was administered via the drinking water (5 mg/kg/day) for a period of two weeks to very young (day 25) and somewhat older (day 50) rats." | 1.30 | Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. ( Bagli, M; Huether, G; Moll, GH; Rothenberger, A; Rüther, E; Wegerer, V, 1999) |
| "Fluoxetine treatment resulted in a nonsignificant increase in nociceptive response at 30 min posttreatment which returned to the baseline by 1 h." | 1.29 | Serotonin modulation of pain responsiveness in the aged rat. ( Akunne, HC; Soliman, KF, 1994) |
| "[3H]Nisoxetine ([3H]NIS) was used to measure uptake sites for norepinephrine (NE) in the locus coeruleus (LC) of humans." | 1.28 | Effect of age on [3H]nisoxetine binding to uptake sites for norepinephrine in the locus coeruleus of humans. ( Ordway, GA; Tejani-Butt, SM, 1992) |
Research
Studies (73)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.11) | 18.7374 |
| 1990's | 11 (15.07) | 18.2507 |
| 2000's | 25 (34.25) | 29.6817 |
| 2010's | 30 (41.10) | 24.3611 |
| 2020's | 4 (5.48) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Petrascheck, M | 2 |
| Ye, X | 1 |
| Buck, LB | 1 |
| Liang, Z | 1 |
| Jia, Y | 1 |
| Zhao, L | 1 |
| Zhu, R | 1 |
| He, X | 1 |
| Tong, B | 1 |
| Yang, F | 1 |
| Hao, L | 1 |
| Cui, P | 1 |
| Yuan, J | 1 |
| Tunc-Ozcan, E | 1 |
| Brooker, SM | 1 |
| Bonds, JA | 1 |
| Tsai, YH | 1 |
| Rawat, R | 1 |
| McGuire, TL | 1 |
| Peng, CY | 1 |
| Kessler, JA | 1 |
| Wang, H | 2 |
| Xiao, L | 1 |
| Wang, G | 1 |
| Iñiguez, SD | 2 |
| Flores-Ramirez, FJ | 1 |
| Themann, A | 1 |
| Lira, O | 1 |
| Duda, W | 1 |
| Kubera, M | 2 |
| Kreiner, G | 1 |
| Curzytek, K | 1 |
| Detka, J | 1 |
| Głombik, K | 1 |
| Ślusarczyk, J | 1 |
| Basta-Kaim, A | 2 |
| Budziszewska, B | 2 |
| Lasoń, W | 1 |
| Regulska, M | 1 |
| Leśkiewicz, M | 1 |
| Roman, A | 1 |
| Zelek-Molik, A | 1 |
| Nalepa, I | 1 |
| Kiryanova, V | 1 |
| Meunier, SJ | 1 |
| Dyck, RH | 1 |
| Connor, DA | 1 |
| Gould, TJ | 1 |
| Sun, Y | 1 |
| Sun, X | 1 |
| Qu, H | 1 |
| Zhao, S | 1 |
| Xiao, T | 1 |
| Zhao, C | 1 |
| Kalogeraki, E | 1 |
| Pielecka-Fortuna, J | 1 |
| Löwel, S | 1 |
| Masrour, FF | 1 |
| Peeri, M | 1 |
| Azarbayjani, MA | 1 |
| Hosseini, MJ | 1 |
| Eavri, R | 1 |
| Shepherd, J | 1 |
| Welsh, CA | 1 |
| Flanders, GH | 1 |
| Bear, MF | 1 |
| Nedivi, E | 1 |
| Micheli, L | 1 |
| Ceccarelli, M | 1 |
| D'Andrea, G | 1 |
| Costanzi, M | 1 |
| Giacovazzo, G | 1 |
| Coccurello, R | 1 |
| Caruso, C | 1 |
| Tirone, F | 1 |
| Bersani, G | 1 |
| Meco, G | 1 |
| Denaro, A | 1 |
| Liberati, D | 1 |
| Colletti, C | 1 |
| Nicolai, R | 1 |
| Bersani, FS | 1 |
| Koverech, A | 1 |
| Francis-Oliveira, J | 1 |
| Ponte, B | 1 |
| Barbosa, AP | 1 |
| Veríssimo, LF | 1 |
| Gomes, MV | 1 |
| Pelosi, GG | 1 |
| Britto, LR | 1 |
| Moreira, EG | 1 |
| Darcy, MJ | 1 |
| Trouche, S | 1 |
| Jin, SX | 1 |
| Feig, LA | 1 |
| Ohira, K | 2 |
| Takeuchi, R | 1 |
| Iwanaga, T | 1 |
| Miyakawa, T | 3 |
| Sarkar, A | 1 |
| Chachra, P | 1 |
| Kennedy, P | 1 |
| Pena, CJ | 1 |
| Desouza, LA | 1 |
| Nestler, EJ | 1 |
| Vaidya, VA | 1 |
| Bourke, CH | 2 |
| Glasper, ER | 1 |
| Neigh, GN | 1 |
| Steiner, H | 1 |
| Warren, BL | 2 |
| Van Waes, V | 1 |
| Bolaños-Guzmán, CA | 2 |
| Li, Y | 2 |
| Abdourahman, A | 1 |
| Tamm, JA | 1 |
| Pehrson, AL | 1 |
| Sánchez, C | 2 |
| Gulinello, M | 2 |
| Olivares-Nazario, M | 2 |
| Fernández-Guasti, A | 3 |
| Martínez-Mota, L | 2 |
| Rangaraju, S | 1 |
| Solis, GM | 1 |
| Andersson, SI | 1 |
| Gomez-Amaro, RL | 1 |
| Kardakaris, R | 1 |
| Broaddus, CD | 1 |
| Niculescu, AB | 1 |
| Reyes, R | 2 |
| Wolkers, CPB | 1 |
| Serra, M | 1 |
| Barbosa Júnior, A | 1 |
| Urbinati, EC | 1 |
| Mason, SS | 1 |
| Baker, KB | 1 |
| Davis, KW | 1 |
| Pogorelov, VM | 1 |
| Malbari, MM | 1 |
| Ritter, R | 1 |
| Wray, SP | 1 |
| Gerhardt, B | 1 |
| Lanthorn, TH | 1 |
| Savelieva, KV | 1 |
| Parise, EM | 1 |
| Alcantara, LF | 1 |
| Schuh, B | 1 |
| Maffeo, ML | 1 |
| Manojlovic, Z | 1 |
| Couillard-Despres, S | 1 |
| Wuertinger, C | 1 |
| Kandasamy, M | 1 |
| Caioni, M | 1 |
| Stadler, K | 1 |
| Aigner, R | 1 |
| Bogdahn, U | 1 |
| Aigner, L | 1 |
| Hodes, GE | 1 |
| Yang, L | 1 |
| Van Kooy, J | 1 |
| Santollo, J | 1 |
| Shors, TJ | 1 |
| Kobayashi, K | 1 |
| Ikeda, Y | 1 |
| Sakai, A | 1 |
| Yamasaki, N | 1 |
| Haneda, E | 1 |
| Suzuki, H | 1 |
| Duncan, MJ | 1 |
| Hester, JM | 1 |
| Hopper, JA | 1 |
| Franklin, KM | 1 |
| Isingrini, E | 1 |
| Belzung, C | 1 |
| d'Audiffret, A | 1 |
| Camus, V | 1 |
| Liu, JX | 1 |
| Pinnock, SB | 1 |
| Herbert, J | 2 |
| Lee, LJ | 2 |
| Capello, CF | 1 |
| Ritchie, JC | 1 |
| Stowe, ZN | 1 |
| Newport, DJ | 1 |
| Nemeroff, A | 1 |
| Owens, MJ | 1 |
| Récamier-Carballo, S | 1 |
| Estrada-Camarena, E | 1 |
| Doosti, MH | 1 |
| Bakhtiari, A | 1 |
| Zare, P | 1 |
| Amani, M | 1 |
| Majidi-Zolbanin, N | 1 |
| Babri, S | 1 |
| Salari, AA | 1 |
| Yau, JL | 1 |
| Hibberd, C | 1 |
| Noble, J | 1 |
| Seckl, JR | 1 |
| O'Leary, KT | 1 |
| Leslie, FM | 1 |
| Shirokawa, T | 1 |
| Ishida, Y | 1 |
| Isobe, K | 1 |
| Akhisaroglu, M | 1 |
| Manev, R | 1 |
| Akhisaroglu, E | 1 |
| Uz, T | 1 |
| Manev, H | 1 |
| Kenis, G | 1 |
| Bosmans, E | 1 |
| Kajta, M | 1 |
| Scharpe, S | 1 |
| Maes, M | 1 |
| Devanand, DP | 1 |
| Nobler, MS | 1 |
| Cheng, J | 1 |
| Turret, N | 1 |
| Pelton, GH | 1 |
| Roose, SP | 1 |
| Sackeim, HA | 1 |
| Zhao, CS | 1 |
| Puurunen, K | 1 |
| Schallert, T | 1 |
| Sivenius, J | 1 |
| Jolkkonen, J | 1 |
| Moore, TL | 1 |
| Schettler, SP | 1 |
| Killiany, RJ | 1 |
| Herndon, JG | 1 |
| Luebke, JI | 1 |
| Moss, MB | 1 |
| Rosene, DL | 1 |
| Landry, M | 1 |
| Frasier, M | 1 |
| Chen, Z | 1 |
| Van De Kar, LD | 1 |
| Zhang, Y | 1 |
| Garcia, F | 1 |
| Battaglia, G | 1 |
| Huang, GJ | 1 |
| Kim, J | 1 |
| Riggs, KW | 1 |
| Misri, S | 1 |
| Kent, N | 1 |
| Oberlander, TF | 1 |
| Grunau, RE | 1 |
| Fitzgerald, C | 1 |
| Rurak, DW | 1 |
| Simonová, Z | 1 |
| Dutt, J | 1 |
| Chang, YC | 1 |
| Tzeng, SF | 1 |
| Yu, L | 1 |
| Huang, AM | 1 |
| Lee, HT | 1 |
| Huang, CC | 1 |
| Ho, CJ | 1 |
| Shintani, N | 1 |
| Hashimoto, H | 1 |
| Tanaka, K | 1 |
| Kawagishi, N | 1 |
| Kawaguchi, C | 1 |
| Hatanaka, M | 1 |
| Ago, Y | 1 |
| Matsuda, T | 1 |
| Baba, A | 1 |
| Lagace, DC | 1 |
| Fischer, SJ | 1 |
| Eisch, AJ | 1 |
| Bian, X | 1 |
| Patel, B | 1 |
| Dai, X | 1 |
| Galligan, JJ | 1 |
| Swain, G | 1 |
| Aguilar, E | 1 |
| Ranchal, A | 1 |
| Tena-Sempere, M | 1 |
| Pinilla, L | 1 |
| Akunne, HC | 1 |
| Soliman, KF | 1 |
| Altamura, AC | 1 |
| Moro, AR | 1 |
| Percudani, M | 1 |
| Grilly, DM | 1 |
| Pistell, PJ | 1 |
| McReynolds, AM | 1 |
| Meyer, JS | 1 |
| Smith, JE | 1 |
| Lakoski, JM | 1 |
| Bastos, EF | 1 |
| Marcelino, JL | 1 |
| Amaral, AR | 1 |
| Serfaty, CA | 1 |
| Wegerer, V | 1 |
| Moll, GH | 2 |
| Bagli, M | 1 |
| Rothenberger, A | 2 |
| Rüther, E | 2 |
| Huether, G | 2 |
| Mehnert, C | 1 |
| Wicker, M | 1 |
| Bock, N | 1 |
| Hansson, SR | 1 |
| Hoffman, BJ | 1 |
| Laudenslager, ML | 1 |
| Clarke, AS | 1 |
| Yoshimoto, K | 1 |
| Kato, B | 1 |
| Ueda, S | 1 |
| Noritake, K | 1 |
| Sakai, K | 1 |
| Shibata, M | 1 |
| Hori, M | 1 |
| Kawano, H | 1 |
| Takeuchi, Y | 1 |
| Wakabayashi, Y | 1 |
| Yasuhara, M | 1 |
| Clineschmidt, BV | 1 |
| Zacchei, AG | 1 |
| Totaro, JA | 1 |
| Pflueger, AB | 1 |
| McGuffin, JC | 1 |
| Wishousky, TI | 1 |
| Morgan, WW | 1 |
| Herbert, DC | 1 |
| Khan, IA | 1 |
| Thomas, P | 1 |
| Tejani-Butt, SM | 1 |
| Ordway, GA | 1 |
| Alper, RH | 1 |
| Bero, LA | 1 |
| Kuhn, CM | 1 |
Clinical Trials (4)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159] | Phase 2 | 52 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability[NCT00525226] | 1,431 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder[NCT01852383] | Phase 4 | 30 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Cortex Motor Function Reorganization in Stroke Patients: A Longitudinal fMRI Study[NCT04794673] | 36 participants (Actual) | Observational | 2020-01-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change in Cornell Dysthymia Rating Scale Scores From Week 0 to Week 12
Cornell Dysthymia Rating Scale scores from range 0-64. Lower or decreasing scores represent decreased severity and a better outcome, while higher or increasing scores represent more severe depression and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Week 0 and 12
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 28.8 |
Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks.
The research rater completed the 24-item Hamilton Rating Scale for Depression (HAM-D) and documented the scores on each visit. Hamilton Rating Scale for Depression scores range from 0-50 with low scores or decreasing scores representing decreased severity and better outcome, and higher scores or increasing scores representing more severe depressive symptoms and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Screen (0) and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 8 |
Change in the Treatment Emergent Symptom Scale (TESS) Total Score From Week 0 to Week 12.
The Treatment Emergent Symptom Scale (TESS) documents the presence of common side effects. There are 26 items and the total score range is 0-26. Low scores or decrease in scores represent less side effects and high scores or increase in scores represent more side effects. The change in side effect severity scores was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: 0 and 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Duloxetine | 5.2 |
Maximum Duloxetine Oral Dose
Maximum duloxetine oral dose (NCT01852383)
Timeframe: Week 0, 1, 2, 4, 6, 8, 10, 12
| Intervention | mg (Mean) |
|---|---|
| Duloxetine | 101 |
Reviews
3 reviews available for fluoxetine and Aging
| Article | Year |
|---|---|
Neuroplasticity and behavioral effects of fluoxetine after experimental stroke.
Topics: Aging; Animals; Brain; Fluoxetine; Humans; Neurogenesis; Neuronal Plasticity; Neurons; Selective Ser | 2017 |
Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior.
Topics: Aging; Animals; Behavior, Animal; Brain; Child; Disease Models, Animal; Fluoxetine; Humans; Methylph | 2014 |
Clinical pharmacokinetics of fluoxetine.
Topics: Administration, Oral; Aged; Aging; Biological Availability; Dose-Response Relationship, Drug; Drug I | 1994 |
Trials
3 trials available for fluoxetine and Aging
| Article | Year |
|---|---|
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Melli | 2021 |
L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine.
Topics: Acetylcarnitine; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cognitive Dysfunction; Diagn | 2013 |
Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.
Topics: Age Factors; Aged; Aging; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method | 2005 |
Other Studies
67 other studies available for fluoxetine and Aging
| Article | Year |
|---|---|
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
Topics: Aging; Animals; Antidepressive Agents; Caenorhabditis elegans; Caloric Restriction; Humans; Longevit | 2007 |
Hippocampal BMP signaling as a common pathway for antidepressant action.
Topics: Aging; Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Bone Morphogenetic Pro | 2021 |
Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Body Weight; Depression; Fluoxetine; Food | 2020 |
Adolescent Fluoxetine Exposure Induces Persistent Gene Expression Changes in the Hippocampus of Adult Male C57BL/6 Mice.
Topics: Aging; Animals; Fluoxetine; Gene Expression Regulation; Hippocampus; Insulin Receptor Substrate Prot | 2021 |
Suppression of pro-inflammatory cytokine expression and lack of anti-depressant-like effect of fluoxetine in lipopolysaccharide-treated old female mice.
Topics: Aging; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Cytokines; Depres | 2017 |
Behavioural outcomes of adult female offspring following maternal stress and perinatal fluoxetine exposure.
Topics: Aging; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Female; Fluoxetine; Ma | 2017 |
Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.
Topics: Aging; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Conditioning, Psychological; Fear; Fluox | 2017 |
Environmental enrichment accelerates ocular dominance plasticity in mouse visual cortex whereas transfer to standard cages resulted in a rapid loss of increased plasticity.
Topics: Aging; Animal Husbandry; Animals; Dominance, Ocular; Environment; Female; Fluoxetine; Mice; Mice, In | 2017 |
Voluntary Exercise During Adolescence Mitigated Negative the Effects of Maternal Separation Stress on the Depressive-Like Behaviors of Adult Male Rats: Role of NMDA Receptors.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Hippocampu | 2018 |
Interneuron Simplification and Loss of Structural Plasticity As Markers of Aging-Related Functional Decline.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Dendrites; Evoked Potentials, Visual; Fluo | 2018 |
Fluoxetine or Sox2 reactivate proliferation-defective stem and progenitor cells of the adult and aged dentate gyrus.
Topics: Aging; Animals; Cell Proliferation; Dentate Gyrus; Fluoxetine; Genetic Vectors; Lateral Ventricles; | 2018 |
Fluoxetine exposure during pregnancy and lactation: Effects on acute stress response and behavior in the novelty-suppressed feeding are age and gender-dependent in rats.
Topics: Aging; Amygdala; Animals; Female; Fluoxetine; Lactation; Male; Paraventricular Hypothalamic Nucleus; | 2013 |
Age-dependent role for Ras-GRF1 in the late stages of adult neurogenesis in the dentate gyrus.
Topics: Aging; Animals; Animals, Newborn; Animals, Suckling; Cell Division; Cell Survival; Dentate Gyrus; Di | 2014 |
Chronic fluoxetine treatment reduces parvalbumin expression and perineuronal nets in gamma-aminobutyric acidergic interneurons of the frontal cortex in adult mice.
Topics: Aging; Animals; Apoptosis; CA3 Region, Hippocampal; Calbindin 2; Cell Count; Fluoxetine; Frontal Lob | 2013 |
Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior.
Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Anxiety Disorders; Butyr | 2014 |
SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat.
Topics: Aging; Animals; Behavior, Animal; Depression; Fluoxetine; Male; Methylcellulose; Rats; Rats, Wistar; | 2014 |
Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice.
Topics: Aging; Animals; Antidepressive Agents; Cell Proliferation; Cognition Disorders; Female; Fluoxetine; | 2015 |
Age-related changes in the antidepressant-like effect of desipramine and fluoxetine in the rat forced-swim test.
Topics: Aging; Animals; Antidepressive Agents; Depressive Disorder; Desipramine; Disease Models, Animal; Dos | 2016 |
Atypical antidepressants extend lifespan of Caenorhabditis elegans by activation of a non-cell-autonomous stress response.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Caenorhabditis elegans; Caenorhabditis ele | 2015 |
Sex and age differences in the antidepressant-like effect of fluoxetine in the forced swim test.
Topics: Aging; Animals; Antidepressive Agents; Dose-Response Relationship, Drug; Estrous Cycle; Female; Fluo | 2017 |
Acute fluoxetine treatment increases aggressiveness in juvenile matrinxã (Brycon amazonicus).
Topics: Aggression; Aging; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Characiforme | 2017 |
Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice.
Topics: Aging; Animals; Antidepressive Agents; Cognition; Cohort Studies; Depression; Duloxetine Hydrochlori | 2017 |
Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains.
Topics: Aging; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Fluoxetine; Hindlimb Suspension; | 2009 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De | 2009 |
Ageing abolishes the effects of fluoxetine on neurogenesis.
Topics: Age Factors; Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Brain; Brom | 2009 |
Prozac during puberty: distinctive effects on neurogenesis as a function of age and sex.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Bromodeoxyuridine; Cell Proliferation; Cel | 2009 |
Reversal of hippocampal neuronal maturation by serotonergic antidepressants.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Biomarkers; Calbindins; Down-Regulation; F | 2010 |
The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors.
Topics: Aging; Animals; Circadian Rhythm; Cricetinae; Fluoxetine; Gastrin-Releasing Peptide; Male; Motor Act | 2010 |
Chronic treatment with fluoxetine for more than 6 weeks decreases neurogenesis in the subventricular zone of adult mice.
Topics: Aging; Animals; Bromodeoxyuridine; Calbindins; Cell Count; Cell Proliferation; Cerebral Ventricles; | 2011 |
Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging.
Topics: Aging; Animals; Biomarkers; Body Weight; Depression; Disease Models, Animal; Fluoxetine; Grooming; H | 2011 |
Novel control by the CA3 region of the hippocampus on neurogenesis in the dentate gyrus of the adult rat.
Topics: Aging; Animals; Bromodeoxyuridine; CA3 Region, Hippocampal; Calbindins; Cell Count; Cell Proliferati | 2011 |
Neonatal fluoxetine exposure alters motor performances of adolescent rats.
Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Fluoxetine; Male; Motor | 2012 |
Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk.
Topics: Aging; Animals; Anxiety; Brain; Central Nervous System; Female; Fetus; Fluoxetine; Image Processing, | 2011 |
Synergistic effect of estradiol and fluoxetine in young adult and middle-aged female rats in two models of experimental depression.
Topics: Aging; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Depression; Disease | 2012 |
Impacts of early intervention with fluoxetine following early neonatal immune activation on depression-like behaviors and body weight in mice.
Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Behavior, Animal; Body W | 2013 |
The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats.
Topics: Aging; Animals; Brain; Fluoxetine; In Situ Hybridization; Male; Maze Learning; Memory; Rats; Rats, I | 2002 |
Developmental regulation of nicotinic acetylcholine receptor-mediated [3H]norepinephrine release from rat cerebellum.
Topics: Age Factors; Aging; Animals; Animals, Newborn; Cerebellum; Dose-Response Relationship, Drug; Female; | 2003 |
Age-related changes in the release and uptake activity of presynaptic axon terminals of rat locus coeruleus neurons.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aging; Animals; Clonidine; Fluoxetine; Fron | 2003 |
Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus.
Topics: Aging; Animals; Blotting, Western; Fluoxetine; Hippocampus; Immunoassay; Injections, Intraperitoneal | 2003 |
Stimulatory effect of antidepressants on the production of IL-6.
Topics: 5-Hydroxytryptophan; Adult; Age Factors; Aging; Antidepressive Agents; Blood Cells; Cyclohexanols; D | 2004 |
Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury.
Topics: Affect; Aggression; Aging; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; B | 2005 |
Cognitive impairment in aged rhesus monkeys associated with monoamine receptors in the prefrontal cortex.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Age Factors; Aging; Analysis of Variance; A | 2005 |
Fluoxetine treatment of prepubescent rats produces a selective functional reduction in the 5-HT2A receptor-mediated stimulation of oxytocin.
Topics: Adrenocorticotropic Hormone; Aging; Animals; Body Weight; Brain; Corticosterone; Dose-Response Relat | 2005 |
Stimulation of neurogenesis in the hippocampus of the adult rat by fluoxetine requires rhythmic change in corticosterone.
Topics: Age Factors; Aging; Animals; Cell Proliferation; Corticosterone; Dentate Gyrus; Depressive Disorder, | 2006 |
Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.
Topics: Adult; Aging; Antidepressive Agents, Second-Generation; Breast Feeding; Depressive Disorder, Major; | 2006 |
Are both embryonic migratory pathways preserved in the adult brain cerebral cortex?
Topics: Aging; Animals; Cell Differentiation; Cell Movement; Cell Proliferation; Cerebral Cortex; Fluoxetine | 2006 |
Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups.
Topics: Aging; Animals; Animals, Newborn; Antimetabolites; Blotting, Western; Brain-Derived Neurotrophic Fac | 2006 |
Serotonergic inhibition of intense jumping behavior in mice lacking PACAP (Adcyap1-/-).
Topics: 5-Hydroxytryptophan; Aging; Animals; Behavior, Animal; Fluoxetine; Mice; Mice, Knockout; Physical Co | 2006 |
Gender and endogenous levels of estradiol do not influence adult hippocampal neurogenesis in mice.
Topics: Aging; Animals; Bromodeoxyuridine; Cell Differentiation; Cell Proliferation; Estradiol; Estrous Cycl | 2007 |
High mucosal serotonin availability in neonatal guinea pig ileum is associated with low serotonin transporter expression.
Topics: Aging; Animals; Animals, Newborn; Calcium; Electrophysiology; Fluoxetine; Guinea Pigs; Hydroxyindole | 2007 |
Serotoninergic control of prolactin secretion in prepubertal male rats.
Topics: 5-Hydroxytryptophan; Aging; Androstane-3,17-diol; Animals; Fluoxetine; Hydroxyindoleacetic Acid; Mal | 1994 |
Serotonin modulation of pain responsiveness in the aged rat.
Topics: Aging; Animals; Drug Synergism; Fluoxetine; Male; Methysergide; Morphine; Pain; Pain Measurement; Ra | 1994 |
Fluoxetine alters the effects of cocaine on vigilance task performance of rats.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Arousal; Cocaine; Discrimination Learning; | 1997 |
Effects of prenatal cocaine exposure on serotonin and norepinephrine transporter density in the rat brain.
Topics: Aging; Animals; Brain; Carrier Proteins; Cocaine; Female; Fluoxetine; Male; Membrane Glycoproteins; | 1998 |
Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus.
Topics: Aging; Animals; Antidepressive Agents; Drug Administration Schedule; Duloxetine Hydrochloride; Elect | 1998 |
Fluoxetine-induced plasticity in the rodent visual system.
Topics: Aging; Animals; Axons; Fluoxetine; Neuronal Plasticity; Rats; Rats, Inbred Strains; Retina; Selectiv | 1999 |
Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life.
Topics: Aging; Animals; Behavior, Animal; Brain Chemistry; Carrier Proteins; Fluoxetine; Growth; Membrane Gl | 1999 |
Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood.
Topics: Aging; Animals; Brain; Brain Stem; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane Trans | 2000 |
Transient expression of a functional serotonin transporter in Merkel cells during late gestation and early postnatal rat development.
Topics: Aging; Animals; Carrier Proteins; Cells, Cultured; Embryonic and Fetal Development; Fluoxetine; Gene | 2000 |
Antidepressant treatment during social challenge prior to 1 year of age affects immune and endocrine responses in adult macaques.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Aging; Animals; Antibody Formation; Antidepressive Agents, | 2000 |
Dopamine and serotonin uptake inhibitors on the release of dopamine and serotonin in the nucleus accumbens of young and aged rats.
Topics: Aging; Animals; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Fluoxetine; Male; Neurons; Nucleus Ac | 2001 |
Fenfluramine and brain serotonin.
Topics: 5-Hydroxytryptophan; Aging; Animals; Animals, Newborn; Brain; Dealkylation; Dihydroxyphenylalanine; | 1978 |
Elevation of serum prolactin levels after the inhibition of serotonin uptake.
Topics: Aging; Animals; Diencephalon; Fluoxetine; Hydroxyindoleacetic Acid; Male; Methysergide; Prolactin; P | 1978 |
Stimulatory effects of serotonin on maturational gonadotropin release in the Atlantic croaker, Micropogonias undulatus.
Topics: Aging; Animals; Female; Fluoxetine; Gonadotropin-Releasing Hormone; Gonadotropins; In Vitro Techniqu | 1992 |
Effect of age on [3H]nisoxetine binding to uptake sites for norepinephrine in the locus coeruleus of humans.
Topics: Adult; Aged; Aging; Autoradiography; Biological Transport; Female; Fluoxetine; Humans; Locus Coerule | 1992 |
Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats.
Topics: Aging; Animals; Blood Pressure; Body Weight; Fluoxetine; Heart Rate; Male; Nitroglycerin; Phenylephr | 1992 |
Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion.
Topics: 5-Hydroxytryptophan; Aging; Animals; Animals, Newborn; Corticosterone; Cyproheptadine; Fluoxetine; G | 1987 |